Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dobutamine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 300 mg - injection, concentrated - excipient ingredients: sulfobutyl betadex sodium; disodium edetate; hydrochloric acid; sodium hydroxide; water for injections - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - dobutamine as hydrochloride - concentrate for solution for infusion - dobutamine as hydrochloride 12.5 mg/ml - dobutamine - dobutamine is indicated for patients who require a positive inotropic support in the short term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures, especially when a low cardiac output is associated with raised pulmonary pressure.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 50 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - dobutamine hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - flucloxacillin sodium monohydrate - powder for solution for injection/infusion - 250 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - flucloxacillin sodium monohydrate - powder for solution for injection/infusion - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin